BG105275A - Производни на tan-1057 - Google Patents

Производни на tan-1057

Info

Publication number
BG105275A
BG105275A BG105275A BG10527501A BG105275A BG 105275 A BG105275 A BG 105275A BG 105275 A BG105275 A BG 105275A BG 10527501 A BG10527501 A BG 10527501A BG 105275 A BG105275 A BG 105275A
Authority
BG
Bulgaria
Prior art keywords
derivatives
tan
humans
animals
diseases
Prior art date
Application number
BG105275A
Other languages
English (en)
Inventor
Michael Brands
Mazen Es-Sayed
Dieter Haebich
Siegfried Raddatz
Joachim Krueger
Rainer Endermann
Reinhold Gahlmann
Hein-Peter Kroll
Frank-Ulrich Geschke
Meijere Armin De
Vladimir Belov
Victor Sokolov
Sergej Kozhushkov
Markus Kordes
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of BG105275A publication Critical patent/BG105275A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)

Abstract

Изобретението се отнася до нови производни на природни продукти, до методи за тяхното получаване, до техни фармацевтични формулировки, както и до приложението им при лечение на заболявания при хора иживотни.
BG105275A 1998-08-27 2001-02-20 Производни на tan-1057 BG105275A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19838998A DE19838998A1 (de) 1998-08-27 1998-08-27 Neue Naturstoffderivate
PCT/EP1999/006124 WO2000012484A1 (de) 1998-08-27 1999-08-20 Tan-1057 derivate

Publications (1)

Publication Number Publication Date
BG105275A true BG105275A (bg) 2001-11-30

Family

ID=7878913

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105275A BG105275A (bg) 1998-08-27 2001-02-20 Производни на tan-1057

Country Status (25)

Country Link
US (1) US6617332B1 (bg)
EP (1) EP1117652B1 (bg)
JP (1) JP4533535B2 (bg)
KR (1) KR20010099629A (bg)
CN (1) CN1324348A (bg)
AT (1) ATE267816T1 (bg)
AU (1) AU759618B2 (bg)
BG (1) BG105275A (bg)
BR (1) BR9913337A (bg)
CA (1) CA2342102C (bg)
DE (2) DE19838998A1 (bg)
EE (1) EE200100125A (bg)
ES (1) ES2219105T3 (bg)
HK (1) HK1041884A1 (bg)
HR (1) HRP20010135A2 (bg)
HU (1) HUP0103316A3 (bg)
ID (1) ID28365A (bg)
IL (1) IL141325A0 (bg)
NO (1) NO20010940L (bg)
NZ (1) NZ510153A (bg)
PL (1) PL346143A1 (bg)
SK (1) SK2622001A3 (bg)
TR (1) TR200100637T2 (bg)
WO (1) WO2000012484A1 (bg)
ZA (1) ZA200101038B (bg)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1113008A1 (en) * 1999-12-29 2001-07-04 Pfizer Products Inc. 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives useful as antibacterial and antiprotozoal agents
US20040204404A1 (en) * 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
CA2707790C (en) * 2007-12-20 2015-04-21 Dr. Reddy's Laboratories Limited Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
CN102548956B (zh) 2009-10-15 2014-05-14 国立大学法人德岛大学 二乙烯三胺五醋酸衍生物的制造方法及二乙烯三胺五醋酸衍生物
CN102712657A (zh) 2009-10-16 2012-10-03 Rib-X制药公司 抗微生物化合物和其制备和使用方法
CN107445976A (zh) * 2009-10-16 2017-12-08 梅琳塔治疗公司 抗微生物化合物和其制备和使用方法
NZ599290A (en) * 2009-10-16 2014-10-31 Melinta Therapeutics Inc Antimicrobial compounds and methods of making and using the same
US9193731B2 (en) 2009-10-16 2015-11-24 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
SG194489A1 (en) 2011-04-15 2013-12-30 Melinta Therapeutics Inc Antimicrobial compounds and methods of making and using the same
RU2475479C1 (ru) * 2011-12-23 2013-02-20 Федеральное государственное бюджетное учреждение Министерства здравоохранения и социального развития Российской Федерации "Медицинский радиологический научный центр" (ФГБУ МРНЦ Минздравсоцразвития России) Вазоконстрикторное средство
EP3038623A4 (en) 2013-09-09 2017-04-19 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
SG10201801956SA (en) 2013-09-09 2018-04-27 Melinta Therapeutics Inc Antimicrobial compounds and methods of making and using the same
US10947237B2 (en) 2015-03-11 2021-03-16 BioVersys AG Antimicrobial compounds and methods of making and using the same
JP2019515041A (ja) 2016-05-06 2019-06-06 メリンタ セラピューティクス、 インコーポレイテッドＭｅｌｉｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 抗菌剤ならびにそれを作製および使用する方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2873340B2 (ja) * 1988-04-29 1999-03-24 武田薬品工業株式会社 抗生物質ｔａｎ―１０５７，その製造法および用途
CA2297055A1 (en) * 1997-08-07 1999-02-18 Research Corporation Technologies, Inc. Antibiotic for methicillin resistant bacteria

Also Published As

Publication number Publication date
DE59909607D1 (de) 2004-07-01
US6617332B1 (en) 2003-09-09
NZ510153A (en) 2002-12-20
AU1009900A (en) 2000-03-21
DE19838998A1 (de) 2000-03-09
ZA200101038B (en) 2002-02-07
EE200100125A (et) 2002-06-17
KR20010099629A (ko) 2001-11-09
SK2622001A3 (en) 2001-11-06
JP2002523496A (ja) 2002-07-30
TR200100637T2 (tr) 2001-10-22
AU759618B2 (en) 2003-04-17
HUP0103316A3 (en) 2002-06-28
CA2342102C (en) 2008-10-28
EP1117652A1 (de) 2001-07-25
ID28365A (id) 2001-05-17
NO20010940L (no) 2001-04-23
HUP0103316A2 (hu) 2002-04-29
NO20010940D0 (no) 2001-02-23
JP4533535B2 (ja) 2010-09-01
HK1041884A1 (zh) 2002-07-26
ATE267816T1 (de) 2004-06-15
WO2000012484A1 (de) 2000-03-09
CN1324348A (zh) 2001-11-28
PL346143A1 (en) 2002-01-28
EP1117652B1 (de) 2004-05-26
BR9913337A (pt) 2001-05-15
IL141325A0 (en) 2002-03-10
ES2219105T3 (es) 2004-11-16
CA2342102A1 (en) 2000-03-09
HRP20010135A2 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
NO20012774D0 (no) Preparat og metode hvor det gjöres bruk av eteriske planteoljer
BG106095A (bg) Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
HUP0003351A3 (en) 2-substituted 4,5-diaryl imidazoles, process for producing them, pharmaceutical compositions containing them and their use
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
EP0793660A4 (en) 2-SUBSTITUTED 1,2,5-THIADIAZOLIDIN-3-ON-1,1-DIOXIDES, COMPOSITION AND THEIR USE
BG105275A (bg) Производни на tan-1057
PT2009025E (pt) Método de inibição da actividade dos osteoclastos
ITMI931649A1 (it) Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
DE69831409D1 (de) Chalcon-derivate mit antiproliferativer aktivität
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
BG104179A (bg) Използване на фанхинон за лечението на болестта на алцхаймер
BG102707A (bg) Нови триазолопурини, метод за тяхното получаване и тяхното приложение като лекарствени средства
BG102667A (bg) Състав, съдържащ диосгенин
HU9501925D0 (en) Ortho-amine-substituted benzoyl-guanidine derivatives, process for producing them their pharmaceutical or diagnostical use, and pharmaceutical compositions containing them
GR3034155T3 (en) Water-soluble epipodophyllotoxin derivatives, preparation method therefor, and use thereof as a drug and for treating cancer
IL118218A0 (en) Terpenoidic derivatives and pharmaceutical compositions containing them
EP0744176A3 (en) Methods for inhibiting bone loss
GR3020575T3 (en) New 2-amino-5-cyano-1,4-dihydropyridines, process for their preparation and use in pharmaceutical compositions
ATE548048T1 (de) Oncomodulin zur behandlung von neurologishen erkrankungen
BG103905A (bg) Врс пептидни соли с органозащитна активност, метод за получаването им и използването им в медицината
MX9704035A (es) 1,1-dioxidos de 2-(fosfiniloximetil)-1,2,5-tiadiazolidin-3-ona substituidos y composiciones y metodo de uso de los mismos.
MX9704036A (es) 1,1-dioxidos y composiciones de 2-(2,3,5,6-tetrafluoro-4-piridil)-1,2,5-thiadizaolidin-3-ona y metodo de uso.
NZ268476A (en) 14-substituted marcfortines, preparation and pharmaceutical compositions thereof
MXPA04000953A (es) Derivados sustituidos del acido 5,6,6a,11b-tetrahidro-7-oxa-aza-benzo[c]fluoren-6-carboxilico como antagonista de nmda.